These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 12866719

  • 1. Novel N-[omega-[4-(2-methoxyphenyl)piperazin-1-yl]-ethyl]pyrid-2(1H)-ones with diversified 5-HT1A receptor activity.
    Paluchowska MH, Bugno R, Charakchieva-Minol S, Wesołowska A, Chojnacka-Wójcik E.
    Pol J Pharmacol; 2002; 54(6):641-6. PubMed ID: 12866719
    [Abstract] [Full Text] [Related]

  • 2. Substitution mode of the amide fragment in some new N-[omega-[4-(2-methoxyphenyl)piperazin-1-yl]alkyl]pyrid-2(1H)-ones and their 5-HT1A/5-HT2A activity.
    Paluchowska MH, Bugno R, Charakchieva-Minol S, Bojarski AJ, Wesołowska A.
    Pol J Pharmacol; 2001; 53(4):369-76. PubMed ID: 11990083
    [Abstract] [Full Text] [Related]

  • 3. Isoindol-1-one analogues of 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridyl)-p-iodobenzamido]ethyl]pipera zine (p-MPPI) as 5-HT1A receptor ligands.
    Zhuang ZP, Kung MP, Mu M, Kung HF.
    J Med Chem; 1998 Jan 15; 41(2):157-66. PubMed ID: 9457239
    [Abstract] [Full Text] [Related]

  • 4. 2-H- and 2-acyl-9- [omega-[4-(2-methoxyphenyl)piperazinyl]-alkyl]-1,2,3,4-tetrahydro-beta-carbolines as ligands of 5-HT1A and 5-HT2A receptors.
    Boksa J, Mokrosz MJ, Charakchieva-Minol S, Tatarczyńska E, Kłodzińska A, Wesołowska A, Misztal S.
    Pol J Pharmacol; 2001 Jan 15; 53(5):501-8. PubMed ID: 11990069
    [Abstract] [Full Text] [Related]

  • 5. New 4-[omega-(diarylmethylamino)alkyl]- and 4-[omega-(diarylmethoxy)alkyl]-1-arylpiperazines as selective 5-HT1A/5-HT2A receptor ligands with differentiated in vivo activity.
    Paluchowska MH, Charakchieva-Minol S, Tatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka-Wójcik E.
    Pol J Pharmacol; 2004 Jan 15; 56(6):743-54. PubMed ID: 15662087
    [Abstract] [Full Text] [Related]

  • 6. Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system.
    Paluchowska MH, Duszyńska B, Kłodzińska A, Tatarczyńska E.
    Pol J Pharmacol; 2000 Jan 15; 52(3):209-16. PubMed ID: 11055578
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
    López-Rodríguez ML, Rosado ML, Benhamú B, Morcillo MJ, Sanz AM, Orensanz L, Beneitez ME, Fuentes JA, Manzanares J.
    J Med Chem; 1996 Oct 25; 39(22):4439-50. PubMed ID: 8893838
    [Abstract] [Full Text] [Related]

  • 8. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
    Chojnacka-Wójcik E, Kłodzińska A, Tatarczyńska E, Paluchowska MH.
    Pol J Pharmacol; 1999 Oct 25; 51(5):405-13. PubMed ID: 10817541
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
    López-Rodríguez ML, Morcillo MJ, Rovat TK, Fernández E, Vicente B, Sanz AM, Hernández M, Orensanz L.
    J Med Chem; 1999 Jan 14; 42(1):36-49. PubMed ID: 9888831
    [Abstract] [Full Text] [Related]

  • 10. Synthesis, 5-HT1A and 5-HT2A receptor activity of new 1-phenylpiperazinylpropyl derivatives with arylalkyl substituents in position 7 of purine-2,6-dione.
    Chloń G, Pawłowski M, Duszyńska B, Szaro A, Tatarczńska E, Kłodzińska AL, Chojnacka-Wójcik E.
    Pol J Pharmacol; 2001 Jan 14; 53(4):359-68. PubMed ID: 11990082
    [Abstract] [Full Text] [Related]

  • 11. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
    Paluchowska MH, Mokrosz MJ, Charakchieva-Minol S, Duszyńska B, Kozioł A, Wesołowska A, Stachowicz K, Chojnacka-Wójcik E.
    Pol J Pharmacol; 2003 Jan 14; 55(4):543-52. PubMed ID: 14581712
    [Abstract] [Full Text] [Related]

  • 12. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ, Paluchowska MH, Duszyńska B, Kłodzińska A, Tatarczyńska E, Chojnacka-Wójcik E.
    Bioorg Med Chem; 2005 Mar 15; 13(6):2293-303. PubMed ID: 15727878
    [Abstract] [Full Text] [Related]

  • 13. New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives.
    Berardi F, Colabufo NA, Giudice G, Perrone R, Tortorella V, Govoni S, Lucchi L.
    J Med Chem; 1996 Jan 05; 39(1):176-82. PubMed ID: 8568804
    [Abstract] [Full Text] [Related]

  • 14. 9-substituted 1,2,3,4-tetrahydro-beta-carbolin-1-ones, new 5-HT1A and 5-HT2A receptor ligands.
    Mokrosz MJ, Boksa J, Charakchieva-Minol S, Wesołowska A, Borycz J.
    Pol J Pharmacol; 1999 Jan 05; 51(4):351-6. PubMed ID: 10540967
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of the amide fragment on 5-HT1A receptor activity of some analogs of MP 3022.
    Paluchowska MH, Charakchieva-Minol S, Tatarczyńska E, Kłodzińska A.
    Pol J Pharmacol; 1999 Jan 05; 51(5):415-21. PubMed ID: 10817542
    [Abstract] [Full Text] [Related]

  • 19. Arylpiperazine derivatives of 3-propyl-beta-tetralonohydantoin as new 5-HT1A and 5-HT2A receptor ligands.
    Byrtus H, Pawłowski M, Duszyńska B, Wesołowska A, Chojnacka-Wójcik E, Bojarski AJ.
    Pol J Pharmacol; 2001 Jan 05; 53(4):395-401. PubMed ID: 11990087
    [Abstract] [Full Text] [Related]

  • 20. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
    Delgado M, Caicoya AG, Greciano V, Benhamú B, López-Rodríguez ML, Fernández-Alfonso MS, Pozo MA, Manzanares J, Fuentes JA.
    Eur J Pharmacol; 2005 Mar 21; 511(1):9-19. PubMed ID: 15777774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.